Pharmacological and gene therapy approaches targeting Schwann cells and their associated signaling pathways (e.g., c-Kit, CSF-1R, and iNOS) are attractive and viable options for developing novel ALS therapies, thus potentially addressing peripheral nerve inflammation and pathology more effectively. This evidence concerns the gene NOS2 and amyotrophic lateral sclerosis.